Intellia Therapeutics NTLA Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Intellia Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Intellia Therapeutics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Intellia Therapeutics's additional paid-in capital?
- Intellia Therapeutics (NTLA) reported additional paid-in capital of $3.31B in Q1 2026.
- How has Intellia Therapeutics's additional paid-in capital changed year-over-year?
- Intellia Therapeutics's additional paid-in capital increased by 7.7% year-over-year, from $3.07B to $3.31B.
- What is the long-term trend for Intellia Therapeutics's additional paid-in capital?
- Over 5 years (2020 to 2025), Intellia Therapeutics's additional paid-in capital has grown at a 27.6% compound annual growth rate (CAGR), from $962.17M to $3.26B.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.